ATEZOLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER WITH HIGH PD-L1 EXPRESSION

Abstract

Atezolizumab is a programmed death protein ligand 1 (PD-1) inhibitor, approved for the first-line advanced or metastatic non-small cell lung cancer (NSCLC) monotherapy, when tumor expresses a high programmed death-ligand 1 (PD-L1) level (≥50 proc.), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Atezolizumab significantly prolonged overall survival compared with platinum-based chemotherapy for NSCLC patients with high PD-L1 expression. It is an effective immunotherapy drug for advanced or metastatic NSCLC treatment with high PD-L1 expression.